project id: TCGA-CESC; case submitter id: TCGA-LP-A5U2; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.96; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.79; rna integrity number: 9.4; age at index: 30; days to birth: -11049; ethnicity: not hispanic or latino; gender: female; race: asian; vital status: Alive; year of birth: 1982; age at diagnosis: 11049; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic t: T2a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 9.0; figo stage: Stage IIIB; icd 10 code: C53.9; last known disease status: not reported; morphology: 8384/3; primary diagnosis: Adenocarcinoma, endocervical type; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 226; days to sample procurement: 0; initial weight: 550.0; portion submitter id: TCGA-LP-A5U2-01A-11; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;